Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024

Rhea-AI Summary

Fresenius Medical Care (FMS) will present nearly 75 research abstracts at the American Society of Nephrology's Kidney Week 2024. The company will showcase advancements in hemodiafiltration therapy and its potential to improve patient outcomes. Researchers will share insights from global databases on kidney failure trends, cardiovascular risks, and treatment modalities.

Key highlights include:

• Research on high-volume hemodiafiltration (HVHDF) and its impact on patient outcomes
• Studies on sustainability and equity in kidney care
• Analysis of global databases to drive care improvements
• Leveraging artificial intelligence and advanced analytics for patient care

Fresenius Medical Care received FDA 510(k) clearance for its 5008X Hemodialysis System in February 2024 and plans to introduce hemodiafiltration therapy in its U.S. clinics starting in 2025.

Positive

• Presentation of 75 research abstracts at ASN Kidney Week 2024, demonstrating strong research pipeline
• FDA 510(k) clearance received for 5008X Hemodialysis System in February 2024
• Plans to introduce hemodiafiltration therapy in U.S. clinics starting in 2025
• Advancements in high-volume hemodiafiltration (HVHDF) therapy showing potential for improved patient outcomes
• Leveraging global databases and AI for improved patient care and outcomes

Negative

• None.

Insights

Medical Research Analyst

This presentation at ASN Kidney Week 2024 showcases Fresenius Medical Care's commitment to advancing kidney care globally. Key highlights include:

• Nearly 75 research abstracts covering a wide range of topics
• Focus on hemodiafiltration (HDF) therapy, which shows potential for improved patient outcomes
• Introduction of HDF in U.S. clinics starting 2025, following FDA clearance of the 5008X Hemodialysis System
• Research on mortality risk, hospitalization rates and convective volume achievement in HDF
• Studies on sustainability, equity and global trends in kidney care
• Utilization of AI and advanced analytics for patient care

While this research demonstrates FMC's innovation efforts, the direct impact on financials is not immediately clear. Investors should monitor how these advancements translate into market adoption and revenue growth in the coming years, particularly with the U.S. introduction of HDF therapy.

Financial Analyst

From a financial perspective, this research showcase at ASN Kidney Week 2024 has several implications for Fresenius Medical Care:

1. Market expansion: The introduction of hemodiafiltration (HDF) therapy in U.S. clinics starting 2025 could open up a new revenue stream in a major market.

2. Competitive advantage: Advanced research in areas like AI-driven predictive analytics and global treatment trends may help FMC maintain its leading position in the kidney care market.

3. Long-term growth potential: Investments in sustainable and equitable care solutions could drive patient acquisition and retention, supporting steady revenue growth.

4. Cost management: Improved treatment outcomes and reduced hospitalization rates associated with HDF could lead to better cost management in FMC's clinic network.

While these developments are promising, their financial impact may take time to materialize. Investors should closely monitor adoption rates of new technologies and therapies in key markets.

• A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments.
• Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.
• Nearly 75 abstracts presented across a broad range of cutting-edge research, covering topics from the global impact of dialysis to advancements in kidney care technology, sustainability, and health equity.

BAD HOMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 75 company-affiliated research abstracts at the American Society of Nephrology's (ASN) Kidney Week 2024 taking place October 24-27 in San Diego.

"We are pleased to present research that exemplifies our ongoing commitment to advancing kidney care on a global scale," said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care. "This year's abstracts highlight key innovations in treatment approaches, including high-volume hemodiafiltration, as well as the integration of artificial intelligence. We aim to leverage insights from Fresenius Medical Care's global databases to improve patient outcomes and drive more equitable, sustainable care for people working to live meaningful lives with kidney disease worldwide."

Fresenius Medical Care has provided an educational grant to the American Society of Nephrology in support of an educational symposium during Kidney Week, The Role of Hemodiafiltration in the Management of Dialysis-Dependent Chronic Kidney Failure, on October 25, 2024, 12:45 PM PDT - 01:45 PM PDT.

In recent years, hemodiafiltration (HDF) has been increasingly recognized for the treatment of patients with kidney failure requiring dialysis. HDF uses enhanced convection in combination with diffusion to improve the removal of large solutes such as beta-2-microglobulin and kappa and lambda light chains. While HDF has been used in Europe widely for many years, beginning in 2025, Fresenius Medical Care will gradually introduce this therapy into its Fresenius Kidney Care dialysis clinics in the United States. In February 2024, Fresenius Medical Care received FDA 510(k) clearance for the company's 5008X Hemodialysis System, an HDF and HighVolumeHDF-capable dialysis machine in the U.S.

At the ASN Kidney Week 2024, scientific and medical experts from across Fresenius Medical Care will present research related to many important topics in kidney disease care. Highlights of this year's presentations include:

Advancing High-Volume Hemodiafiltration (HVHDF)

• Mortality Risk on Hemodiafiltration Compared with High-Flux Hemodialysis: Real-World Evidence from a Large Brazilian Cohort: Patients undergoing online hemodiafiltration (HDF) have been associated with better survival compared to those on high-flux hemodialysis (HD). Recently, the use of HDF has grown markedly in Brazil, but there is no robust real-world Brazilian study on the impact of this dialysis modality on patient's outcomes.
• Hemodiafiltration Is Associated with Lower Hospitalization Rates Compared with Hemodialysis in a Singapore Cohort: Hemodialysis (HD) patients suffer from high rates of hospitalization leading to significant morbidity, mortality, and costs. Hemodiafiltration (HDF) has been shown to improve patient outcomes.
• Adequate Convective Volume Can Be Achieved in Majority of Multiethnic Asian Patients Receiving Hemodiafiltration in Singapore: High-volume hemodiafiltration (HDF) has been shown to improve patient outcomes. However, there is a very common concern amongst healthcare practitioners about the feasibility of achieving optimal convective volume (CV) in Asian patients.

Sustainability and Equity in Kidney Care

• High Prevalence and Inequities in Unmet Social Risk in Diverse Urban Patients on Hemodialysis: Health-related social risks (SR) are associated with adverse health outcomes amongst patients with kidney disease. We aimed to identify and analyze SR in a diverse population of hemodialysis (HD) patients.
• Survival Sex Differences among Pediatric and Young Adult Hemodialysis Patients in the Global MONDO Registry: For all age groups, women with ESKD on HD have higher rates of cardiovascular (CV) events compared to men, but their all-cause mortality is reduced. Survival in pediatric and young adult HD patients (pts) from across the globe is understudied.
• Canadian Wildfires of 2023 and Risk of Mortality and Hospitalization Among ESKD Patients: Climate change driven droughts are increasing frequency and intensity of wildfires, a significant source of air pollution. Smoke plumes from the 2023 Canadian wildfires travelled long distances and negatively impacted air quality across large swaths of eastern US. We investigated the association between exposure to 2023 Canadian wildfire-related air pollutants and risk of mortality and hospitalization among hemodialysis patients in New England, the Mid-Atlantic, and the Midwest U.S.

Harnessing the Power of Global Databases to Drive Care

• Cardiovascular Morbidity Patterns in Patients on Dialysis Globally in Apollo Dial DB: Cardiovascular diseases (CVDs) affect most people with kidney failure but are undefined globally. We aimed to analyze CVD prevalence among dialysis patients treated in 40 countries across six continents, as represented in the first version of a global dialysis database called Apollo Dial DB.
• Profiles of Home Medication Use in Patients on Dialysis Globally: Global patterns of medication use in dialysis are undefined. This project aims to provide a real-world view of home medication use in dialysis using a global dialysis dataset from 40 countries. The most common prescribed medications administered at home by patients were compared by modality.
• Changes in Fluid Overload during the First 6 Months of Dialysis among More than 13,000 Patients: Fluid overload (FO) is a recognized risk factor for mortality in dialysis patients; however, less has been reported on factors related to changes in FO. Whole-body bioimpedance spectroscopy (BIS) has been validated for hydration assessment. We used Body Composition Monitor (BCM) data, a whole-body BIS, to evaluate changes in the degree of FO during the first 6 months of hemodialysis (HD) or hemodiafiltration (HDF) and characteristics associated with those changes using Apollo Dial DB.

Leveraging Artificial Intelligence (AI), Computational Medicine, and Advanced Analytics for Patient Care

• Arteriovenous Fistula Failure Prediction Using Single Treatment Information: Predicting the natural course of AVF complications with technical surveillance has been an elusive task. We developed a machine learning algorithm assessing the risk of failure of AVF using information collected by the dialysis machine in a single treatment.
• Validation of a Cloud-Based Convolutional Neural Network Classifying Arteriovenous Access Aneurysms in a Multicenter Study: Arteriovenous (AV) access aneurysms may become life-threatening, e.g., in the event of ruptures. We developed an artificial intelligence classification application (ACA) that categorizes aneurysms using AV access images. This study prospectively evaluates ACA's classification of AV aneurysms against physicians specializing in access care.
• Joint Modeling of Longitudinal Ferritin Trajectories and COVID-19 Infections in Native American, Hispanic, and White Patients on Hemodialysis: American Indians/Alaska Natives (AIAN) and Hispanic individuals in the U.S. are overrepresented in the hemodialysis (HD) population and were hardest hit by COVID-19. Early in the pandemic, hyperferritinemia was linked to COVID-19 infections. Joint modeling learns from both longitudinal and time-to-event data for predictive accuracy and dynamic estimation. We investigated the predictive utility of ferritin w/ COVID-19 infection in a cohort of AIAN, Hispanic and White HD patients.

For more information about Fresenius Medical Care's presence at ASN Kidney Week 2024, please visit https://www.freseniusmedicalcare.com/en/ASN-2024/.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,757 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 311,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-showcases-research-and-innovations-in-kidney-care-at-american-society-of-nephrology-asn-kidney-week-2024-302281930.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What is Fresenius Medical Care (FMS) presenting at ASN Kidney Week 2024?

Fresenius Medical Care (FMS) is presenting nearly 75 research abstracts at ASN Kidney Week 2024, covering topics such as advancements in hemodiafiltration therapy, sustainability in kidney care, global database analysis, and the use of artificial intelligence in patient care.

When did Fresenius Medical Care (FMS) receive FDA clearance for its 5008X Hemodialysis System?

Fresenius Medical Care (FMS) received FDA 510(k) clearance for its 5008X Hemodialysis System in February 2024.

When will Fresenius Medical Care (FMS) introduce hemodiafiltration therapy in its U.S. clinics?

Fresenius Medical Care (FMS) plans to gradually introduce hemodiafiltration therapy in its Fresenius Kidney Care dialysis clinics in the United States beginning in 2025.

What are some key research areas Fresenius Medical Care (FMS) is focusing on at ASN Kidney Week 2024?

Key research areas for Fresenius Medical Care (FMS) at ASN Kidney Week 2024 include advancing high-volume hemodiafiltration (HVHDF), sustainability and equity in kidney care, harnessing global databases to drive care improvements, and leveraging artificial intelligence for patient care.